Memorial Sloan Kettering Cancer Center is pleased to announce

CLINICAL APPLICATION OF CAR T CELLS

MARCH 10-11, 2016

Conference Location:
Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street, New York, NY 10065
Featuring national and international experts including world renowned Keynote Speakers, and a cocktail reception and dinner at The Museum of the City of New York on Thursday, March 10, 2016.

Keynote Speakers

Zelig Eshhar, PhD
Professor of Immunology
The Weizmann Institute of Science, Israel

Michel Sadelain, MD, PhD
Director, Center for Cell Engineering
Memorial Sloan Kettering Cancer Center

Cocktail Reception & Dinner

Please join us on the evening of Thursday, March 10th for a cocktail reception, dinner, and tour at THE MUSEUM OF THE CITY OF NEW YORK.

*RSVP details will be sent with registration confirmation.
Course Overview

Chimeric antigen receptor (CAR) T-cell (‘Living Drug’) immunotherapy is showing promising results in the treatment of cancers. There are nine ongoing clinical trials (Phase I & II) at Memorial Sloan Kettering (MSK) and more are on track to be initiated next year.

Over the years, MSK has accumulated a breadth of knowledge about developing and translating these clinical trials from bench to bedside – choosing the ideal antigen target, constructing clinical grade CARs and vectors, investigating CARs in clinically relevant models, manufacturing, quality control, developing protocols for FDA approval, optimizing consent forms that cover emerging ethical issues, managing complications, and conducting world-class correlative science.

In addition to the MSK faculty, national and international experts will discuss clinical and translational aspects of CARs, both for hematological malignancies and solid tumors.

TARGET AUDIENCE
The target audience is medical oncologists and oncology fellows in training, basic scientists and research fellows in training, immunologists, and surgeons with interest in tumor immunology and immunotherapy.

PRESENTATIONS & PANEL DISCUSSION TOPICS

- CAR mechanics
- CD19-targeted CARs: Clinical trials and beyond
- CARs to target Non-Hodgkin Lymphoma
- State of the art clinical-grade CAR T-cell manufacturing and production
- Beyond regulatory approvals: NIH RAC, IRB, IND, and FDA
- Driving CARs through solid tumors
- Safety belts for CARs
- Next-generation CARs

For more information, or to register, visit:
WWW.MSKCC.ORG/CARTcell
Course Faculty

**MSK COURSE DIRECTOR**  
Prasad S. Adusumilli, MD, FACS, FCCP  
Member, Center for Cell Engineering & Center for Cellular Therapeutics  
Deputy Chief, Thoracic Surgery Service

**MSK COURSE CO-DIRECTORS**  
Renier J. Brentjens, MD, PhD  
Director, Center for Cellular Therapeutics  
Michel Sadelain, MD, PhD  
Director, Center for Cell Engineering

**MSK FACULTY**  
Kevin J. Curran, MD  
Pediatrics  
Sergio A. Giralt, MD  
Chief, Bone Marrow Transplant  
Roisin E. O’Cearbhaill, MD  
Gynecologic Medicine  
Jae Park, MD  
Leukemia  
Isabelle Riviere, PhD  
Cell Therapy & Cell Engineering  
Paul Sabbatini, MD  
Deputy Physician-in-Chief  
Craig S. Sauter, MD  
Bone Marrow Transplant  
David A. Scheinberg, MD, PhD  
Chair, Molecular Pharmacology Program  
Marcel R.M. van den Brink, MD, PhD  
Division Head, Hematologic Oncology – Medicine  
Roger S. Wilson, MD  
Institutional Review Board  
Jedd D. Wolchok, MD, PhD  
Chief, Melanoma & Immunotherapeutics

**INVITED FACULTY**  
Steven M. Albelda, MD  
University of Pennsylvania  
Christine Brown, PhD  
City of Hope  
Laurence J. N. Cooper, MD, PhD  
MD Anderson  
Marco L. Davila, MD, PhD  
Moffitt Cancer Center  
Soldano Ferrone, MD, PhD  
Massachusetts General Hospital  
Noelle Frey, MD, MSCE  
University of Pennsylvania  
Rebecca A. Gardner, MD  
Seattle Children’s Hospital  
Adrian P. Gee, PhD  
Baylor Medical Center  
David Gilham, PhD  
University of Manchester  
Stephen Gottschalk, MD  
Baylor Medical Center  
Michael C. V. Jensen, MD  
Seattle Children’s Hospital  
James N. Kochenderfer, MD  
National Cancer Institute  
Daniel W. Lee, MD  
National Cancer Institute  
Bruce L. Levine, PhD  
University of Pennsylvania  
John Maher, PhD, FRCPath  
King’s College London  
Shannon L. Maude, MD, PhD  
Children’s Hospital of Philadelphia  
Marcela V. Maus, MD, PhD  
Massachusetts General Hospital  
David L. Porter, MD  
University of Pennsylvania  
Stephen J. Schuster, MD  
University of Pennsylvania  
Cameron J. Turtle, MD, PhD  
Fred Hutchinson Cancer Center
THURSDAY, MARCH 10

8:00-8:45  BREAKFAST & REGISTRATION
8:45-8:50  WELCOME
8:50-9:00  INAUGURAL ADDRESS

NEW DIRECTIONS IN T-CELL ENGINEERING
MODERATORS  Michel Sadelain, MD, PhD
             Marcel R.M. van den Brink, MD, PhD

9:00-9:20  Challenges in CAR Targeting – New Approaches to Target the ErbB Family
           John Maher, PhD, FRCPath

9:20-9:40  Crafting CAR T-cell Products of Defined Cellular Composition
           Michael C. V. Jensen, MD

9:40-10:00  Engineering CARs and Cytokines for Therapeutic Applications
            Laurence J. N. Cooper, MD, PhD

10:00-10:15  DISCUSSION

10:15-10:30  COFFEE BREAK

CARS FOR HEMATOLOGICAL MALIGNANCIES – PART I
MODERATORS  Jae Park, MD
             David L. Porter, MD

10:30-10:45  Clinical Trials for B-cell ALL: MSK Experience
             Jae Park, MD

10:45-11:00  Clinical Trials for B-cell ALL: NCI Experience
             Daniel W. Lee, MD

11:00-11:15  Clinical Trials for B-cell ALL: Seattle Children’s Experience
             Rebecca A. Gardner, MD

11:15-11:30  DISCUSSION

11:30-12:00  KEYNOTE ADDRESS
             Zelig Eshhar, PhD

12:00-1:00  LUNCH

PANEL DISCUSSION
MODERATORS  Prasad S. Adusumilli, MD, FACS, FCCP
             Stephen Gottschalk, MD

1:00-2:00  Driving CARs Through Regulatory Approvals & Building a CAR T-Cell Program
           Sergio A. Giralt, MD
           Paul Sabbatini, MD
           Roger S. Wilson, MD

CARS FOR HEMATOLOGICAL MALIGNANCIES – PART II
MODERATORS  John Maher, PhD, FRCPath
             Renier J. Brentjens, MD, PhD

2:00-2:15  CARs for NHL and Myeloma at NCI
           James N. Kochenderfer, MD

2:15-2:30  CARs for CLL at UPenn
           David L. Porter, MD

2:30-2:45  Immunotherapy for NHL with CD19 CAR T cells of Defined Composition
           Cameron J. Turtle, MD, PhD

2:45-3:00  DISCUSSION

3:00-3:15  COFFEE

SAFETY BELTS FOR CARS
MODERATORS  Kevin J. Curran, MD
             Soldano Ferrone, MD, PhD
             Marco L. Davila, MD, PhD

3:15-3:30  CAR T-cell Toxicity Management Algorithms: MSK Approach
           Kevin J. Curran, MD

3:30-3:45  Defining Cytokine Release Syndrome
           Noelle Frey, MD, MSCE

3:45-4:00  Managing Cytokine Release Syndrome
           Daniel W. Lee, MD

4:00-4:15  Potential Toxicities of CAR T cells – Beyond Cytokine Release Syndrome
           Marcela V. Maus, MD, PhD

4:15-4:30  Predicting and Preventing CAR T-cell Toxicity
           Marco L. Davila, MD, PhD

POSTER PRESENTATIONS
MODERATORS  Kevin J. Curran, MD
             Roisin E. O’Cearbhaill, MD
             Christine Brown, PhD

4:30-5:30  Poster Presentations (serving wine and cheese)

6:00-9:00  Cocktail Reception, Museum Tour, and Dinner at
           THE MUSEUM OF THE CITY OF NEW YORK
           1220 5th Avenue, New York
           Confirmations are required. RSVP details will be sent upon registration.
FRIDAY, MARCH 11

8:00-8:45  BREAKFAST
9:00-9:15  INTRODUCTORY REMARKS

CARS FOR SOLID TUMORS
MODERATORS  Prasad S. Adusumilli, MD, FACS, FCCP
             Steven M. Albelda, MD

9:15-9:30  Augmenting CAR T-cell Function in Solid Tumors
          Steven M. Albelda, MD
9:30-9:45  Mesothelin Targeted CARs for Lung,
          Breast Cancers, and Mesothelioma
          Prasad S. Adusumilli, MD, FACS, FCCP
9:45-10:00 HER-2 Targeted CARs for Sarcoma
          Stephen Gottschalk, MD
10:00-10:15 CSPG-4 Targeted CARs for Solid Tumors
            Soldano Ferrone, MD, PhD
10:15-10:30 IL13Ra2 Targeted CARs for Glioma
            Christine Brown, PhD
10:30-10:45 DISCUSSION

10:45-11:00  COFFEE BREAK

11:00-11:15  Immune Response Monitoring in Solid
             Tumor Therapies
             Jedd D. Wolchok, MD, PhD

CARS FOR HEMATOLOGICAL MALIGNANCIES – PART III
MODERATORS  Craig S. Sauter, MD
             Cameron J. Turtle, MD, PhD

11:15-11:30  Phase II CAR T-cell Therapy Trials for
             NHL at UPenn
             Stephen J. Schuster, MD
11:30-11:45  CARs Post Autologous Transplant for
             NHL at MSK
             Craig S. Sauter, MD
11:45-12:00  Clinical Trials for B-cell ALL: UPenn/
             CHOP Pediatric Experience
             Shannon L. Maude, MD, PhD

12:00-1:00  LUNCH
1:00-1:30  KEYNOTE ADDRESS Michel Sadelain, MD, PhD

CAR T-CELL MANUFACTURING
MODERATORS  Isabelle Riviere, PhD
             Adrian P. Gee, PhD
             Bruce L. Levine, PhD

1:30-1:50  Evolution of CAR Manufacturing at MSK
           Isabelle Riviere, PhD
1:50-2:10  Chemistry, Manufacturing, and Controls (CMC)
           for CARs
           Adrian P. Gee, PhD
2:10-2:30  Evolution and Globalization of
           CAR T-Cell Therapies
           Bruce L. Levine, PhD
2:30-2:45  DISCUSSION
2:45-3:10  Bench to Bedside to Biotech
           Renier J. Brentjens, MD, PhD

3:10-3:30  COFFEE

NEXT GENERATION CARS
MODERATORS  David A. Scheinberg, MD, PhD
             David Gilham, PhD

3:30-3:50  Preclinical Development of CAR T cells
           David Gilham, PhD
3:50-4:10  IL-12 Secreting CARs
           Roisin E. O’Cearbhaill, MD
4:10-4:30  Overcoming Antigen Escape by Multiplexing of
           CAR T-cell Targets
           Michael C. V. Jensen, MD
4:30-4:50  Potentiating CARs with Checkpoint Blockade
           Prasad S. Adusumilli, MD, FACS, FCCP
4:50-5:00  CONCLUDING REMARKS
**Registration**

<table>
<thead>
<tr>
<th>EARLY*</th>
<th>GENERAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>$200</td>
<td>$250 Physicians (MDs, PhDs, DOs)</td>
</tr>
<tr>
<td>$75</td>
<td>$100 Residents, Fellows</td>
</tr>
</tbody>
</table>

*Deadline for early registration is February 15, 2016.

To register, please go to:  
WWW.MSKCC.ORG/CARTcell

Registration includes an electronic syllabus and other related handout materials, continental breakfast, lunch, and refreshment breaks. Special meals are available upon request, including vegetarian, kosher, or gluten-free. Please let us know if we can assist you with any special dietary needs.

**ACCOMMODATIONS**

For information on hotels in the area of MSK with discounted rates, please visit: www.mskcc.org/accommodations

**CONTACT**

Office of Continuing Medical Education  
Memorial Sloan Kettering Cancer Center  
633 Third Avenue, 12th Floor  
New York, New York 10017  
(646) 227-2025  
cme@mskcc.org

**ACCRREDITATION STATEMENT**

Memorial Sloan Kettering Cancer Center (MSKCC) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. MSKCC designates this conference for a maximum of 12.75 AMA PRA Category 1 Credits™. Each physician should claim only those hours of credit he/she actually spent in the conference.

**EVALUATION**

A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

**OUTCOMES MEASUREMENT SURVEY**

Six months after the end of the course, an Outcomes Measurement survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

**FACULTY DISCLOSURE**

It is the policy of MSKCC to make every effort to ensure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSKCC are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSKCC requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.